Our Programs

the

initiative

ReLeef

"Industry investments to develop pediatric antibiotic formulations are miniscule — at the same time most deaths from infections involve children below age 10"

Rounded Rectangle: Program 1 New Treatment for Tissue Wasting The objective of our first program is to develop a combination drug for prevention of involuntary weight loss in conjunction with AIDS and other infections. The program is conducted in collaboration with a for-profit partner. The program entails re-positioning of drugs that are already in clinical use for other indications.

Our Programs

It is a paradox of modern time that while half of the global death rate in infectious diseases involves children, the availability of pediatric formulations of simple over-the-counter health supplements, is still limited for half of the global population. The research and development approach of Releef is based on providing existing therapies in a configuration that addresses these unmet medical needs. Our approach is based on four fundamental principles:

• To develop products with extreme safety. The organization is planning to develop products consisting of active ingredients with uncompromised long-standing safety documentation.

• To develop products that can be manufactured at a very low cost. The active ingredients will be manufactured via trivial process chemistry. Our delivery technology will involve safe excipients, which are also very inexpensive to manufacture.

• To develop products targeted for pediatric use. The organization is developing intellectual property around novel packaging formats combined with a new mini-particle technology specifically for pediatric use. This packaging and delivery system allows flexible dosing, taste-free coating and provides extended release compatible with a single daily dose administration.

• To make the program self-sustainable through licensing agreements with for-profit industry. Releef is planning to out-license the rights to sell products based on our intellectual property to for-profit partners. The partners will have rights to manufacture, distribute, and sell products in developed countries. In return, Releef will obtain a royalty stream that can be used for purchase of product for humanitarian use. We believe that for-profit mechanisms are the best way to ensure sustainability.

Rounded Rectangle: Program 2 New Formulation & Packaging Technology for Pediatric Drugs Releef owns intellectual property surrounding a novel formulation concept that allow packaging and dynamic dispensing of solid-form pharmaceuticals. Our vision is that this new technology platform will be useful for the introduction of multiple pediatric health care products including formulation of micronutrients, antibiotics and water biocides.

Rounded Rectangle: Prof. Tamas Bartfai is an Executiver Advisor to Releef. Dr Bartfai is Chair and Professor of the Neurosciences Department at The Scripps Resarch Institute in San Diego. Dr Bartfai who is a former Sr VP of R&D in Roche was one of the initiators of the Science for Humanity program by The International Red Cross.

Program Overview

Home About Us Our programs News How to Participate Contact Us

Initiatives with low risk that can be completed in short time frames...

The Releef Initiative is an IRS 501(c)3 nonprofit charitable organization

Program	2005	2006	2007	2008	2009	2010	2011
Tissue wasting in infectious diseases and cancer
Formulation and dispensing technology for pediatric drugs

	Non-clinical development
	Clinical development